Literature DB >> 9454763

Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.

E Fressinaud1, A Veyradier, F Truchaud, I Martin, C Boyer-Neumann, M Trossaert, D Meyer.   

Abstract

We have evaluated the performance of a new analyzer using high shear stress, the PFA-100 (Platelet Function Analyzer, Dade International, Massy, France), for screening of patients with von Willebrand disease (vWD). Whole citrated blood is aspirated through a capillary to the central aperture of a membrane coated with collagen and with a platelet agonist (either epinephrine or adenosine diphosphate [ADP]). The time required to obtain occlusion of the aperture by a platelet plug is defined as the closure time (CT). We studied 60 patients with different types of vWD and 96 normal subjects. Fourteen subjects with hemophilia and 15 patients with a platelet disorder were also analyzed. When omitting results from two patients with type 2N, the 58 other patients with type 1, type 2A, type 2B, type 3, or acquired vWD all exhibited an abnormal occlusion with collagen-ADP (sensitivity, 100%) and 56 of 58 had an abnormal CT with collagen-epinephrine (sensitivity, 96.5%). Only two patients with mild type 1 were not detected with collagen-epinephrine. In comparison, the bleeding time (BT) was normal in 20 patients: 17 with type 1, two with type 2A, and one with acquired vWD (sensitivity, 65.5%). The specificity of the PFA-100 was over 95% with both types of cartridges. Thus, the analyzer is well adapted to routine testing, as it has the advantages of simplicity and ease of execution, and demonstrates a high sensitivity, clearly superior to that of BT, for the screening of patients with vWD.

Entities:  

Mesh:

Year:  1998        PMID: 9454763

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.

Authors:  A J Peters; M Borries; F Gradaus; T W Jax; F C Schoebel; B E Strauer
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

Review 2.  Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures.

Authors:  H M Hussein; T Emiru; A L Georgiadis; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

Review 3.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 4.  Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders.

Authors:  Rogier M Schoeman; Marcus Lehmann; Keith B Neeves
Journal:  Platelets       Date:  2017-05-22       Impact factor: 3.862

5.  [The significance of bleeding disorders in patients with epistaxis].

Authors:  T Taeumer; A de Greiff; I Scharrer; K Papaspyrou; T Mewes; W Mann
Journal:  HNO       Date:  2011-06       Impact factor: 1.284

6.  Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain.

Authors:  Andrew D Atiemo; Ladina S Ng'Alla; Dhananjay Vaidya; Marlene S Williams
Journal:  J Thromb Thrombolysis       Date:  2007-06-07       Impact factor: 2.300

7.  Hemostatic abnormalities in adult patients with Marfan syndrome.

Authors:  Katharina T I Kornhuber; Heide Seidel; Claudia Pujol; Christian Meierhofer; Franz Röschenthaler; Axel Pressler; Alexander Stöckl; Nicole Nagdyman; Rhoia C Neidenbach; Philipp von Hundelshausen; Martin Halle; Stefan Holdenrieder; Peter Ewert; Harald Kaemmerer; Michael Hauser
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

8.  Von Willebrand disease: an overview.

Authors:  K Pavani Bharati; U Ram Prashanth
Journal:  Indian J Pharm Sci       Date:  2011-01       Impact factor: 0.975

9.  There's something fishy about this bleeding.

Authors:  Adam R Berliner; Derek M Fine
Journal:  NDT Plus       Date:  2011-04-12

10.  The Prevalence of von Willebrand Disease and Significance of in Vitro Bleeding Time (PFA-100) in von Willebrand Disease Screening in the İzmir Region.

Authors:  Fatih Sap; Tülay Kavaklı; Kaan Kavaklı; Ceyhun Dizdarer
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.